193 related articles for article (PubMed ID: 8636748)
1. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Chappell R; Hammond D; Bleyer WA
J Clin Oncol; 1996 Feb; 14(2):389-98. PubMed ID: 8636748
[TBL] [Abstract][Full Text] [Related]
2. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Coccia PF; Bleyer WA; Lukens JN; Siegel SE; Sather HN; Hammond GD
J Clin Oncol; 1989 Dec; 7(12):1807-15. PubMed ID: 2685179
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
[TBL] [Abstract][Full Text] [Related]
4. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
[TBL] [Abstract][Full Text] [Related]
5. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
6. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
[TBL] [Abstract][Full Text] [Related]
7. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
8. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
Yetgin S; Cetin M
Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
[TBL] [Abstract][Full Text] [Related]
9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
10. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
11. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
12. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
[TBL] [Abstract][Full Text] [Related]
13. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
15. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia.
Visser JH; Wessels G; Hesseling PB; Louw I; Oberholster E; Mansvelt EP
Pediatr Hematol Oncol; 2001; 18(3):187-91. PubMed ID: 11293286
[TBL] [Abstract][Full Text] [Related]
17. [Results and experiences with a modified BFM protocol for treatment of recurrences in children with acute lymphoblastic leukemia in East German areas].
Sauerbrey A; Zintl F; Malke H; Reimann M; Maaser M; Domula M; Dörffel W; Eggers G; Exadaktylos P; Kotte W
Klin Padiatr; 1993; 205(4):281-7. PubMed ID: 8377448
[TBL] [Abstract][Full Text] [Related]
18. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
19. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
20. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
